

Special Issue

Advances in Nanomaterial-Based Drug Delivery Systems

Message from the Guest Editor

Dear colleagues, I would like to invite you to contribute new discoveries that may help advance the applications of nanotechnology in drug delivery. Nanotechnology has been utilized in clinics. Despite remarkable progress in the past few decades, challenges are still associated with nanomedicine. Biological barriers limit nanoparticles' delivery of therapeutic drugs to the desired tissues or cells. The low efficiency of clinical translation indicates that there are safety and regulation issues. This Special Issue aims to publish up-to-date progress in engineering novel nanomaterials and formulations for delivering small-molecule and biologic drugs, strategies of enhancing the therapeutic outcome in treating diseases, such as cancer and autoimmune and infectious diseases, and mechanisms of improving the delivery efficiency of nanoparticles. I hope the contributions to this Special Issue will cast some light on improving the therapeutic effect and reducing the side effects of nanoparticle-based drug delivery systems in cancer therapy, gene therapy, and immunotherapy.

Guest Editor

Dr. Donghui Song

Department of Biomedical Engineering, Tufts University, Medford, MA 02155, USA

Deadline for manuscript submissions

closed (31 May 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/191529

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).